Results 31 to 40 of about 7,177,989 (337)

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma

open access: yesMolecular Cancer, 2023
Esophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-related mortality worldwide, with more than half of them occurred in China. Radiotherapy (RT) has been widely used for treating ESCC. However, radiation-induced DNA damage
Lin An, Ming-Yang Li, Qing-Ge Jia
semanticscholar   +1 more source

Immunotherapy for Esophageal Squamous Cell Carcinoma [PDF]

open access: yesCurrent Oncology Reports, 2017
Esophageal squamous cell carcinoma have been frustrating to treat, with slow progress made on extending survival. Immunotherapy targeting immune checkpoints, T cells, and infiltrating lymphocytes has shown promise in early studies. The efficacy of pembrolizumab and nivolumab is encouraging. Anti-chemokine receptors and oncolytic viruses are also making
Kojima, Takashi, Doi, Toshihiko
openaire   +2 more sources

Characteristic and Interplay of Esophageal Microbiota in Esophageal Squamous Cell Carcinoma [PDF]

open access: yesBMC Cancer, 2021
Abstract Background: Esophageal squamous cell carcinoma(ESCC) is severe cancer in the world. The role of esophageal microbiota for ESCC is still uncertain. In the current study, 120 paired tissues from ESCC patients were collected, and 16s rRNA sequencing was performed to explore the esophageal microbiota.
Zheng Lin   +11 more
openaire   +3 more sources

Rare Cutaneous Metastasis From Esophageal Squamous Cell Carcinoma. [PDF]

open access: yesKaohsiung J Med Sci
The Kaohsiung Journal of Medical Sciences, EarlyView.
Cheng SH, Huang YS, Hsiao CE, Hsiao HH.
europepmc   +2 more sources

Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma.

open access: yesCancer Cell, 2023
Neoadjuvant immune checkpoint blockade (ICB) demonstrates promise in operable esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers.
Zhi-Chao Liu   +19 more
semanticscholar   +1 more source

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma [PDF]

open access: yesFrontiers in Cellular and Infection Microbiology, 2021
Microbial imbalances have been well elucidated in esophageal adenocarcinoma. However, few studies address the microbiota in esophageal squamous cell carcinoma (ESCC) and esophagitis (ES). We aimed to explore the association of esophageal microbiota with these patients.
Jiang Zongdan   +4 more
openaire   +4 more sources

How we treat esophageal squamous cell carcinoma

open access: yesESMO Open, 2023
Esophageal squamous cell carcinoma (ESCC) poses a major challenge for clinicians as the prognosis is poor and treatment options are limited. However, recent advances in immunotherapy have significantly changed the treatment algorithm of ESCC.
H. Puhr, G. Prager, A. Ilhan-Mutlu
semanticscholar   +1 more source

N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis

open access: yesNature Communications, 2022
Mis-regulated RNA modifications promote the processing and translation of oncogenic mRNAs to facilitate cancer progression, while the molecular mechanisms remain unclear. Here we reveal that tRNA m7G methyltransferase complex proteins METTL1 and WDR4 are
Hui Han   +18 more
semanticscholar   +1 more source

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

open access: yesNature Communications, 2021
This randomized, open-label, multi-center phase 2 study (NCT03116152) assessed sintilimab, a PD-1 inhibitor, versus chemotherapy in patients with esophageal squamous cell carcinoma after first-line chemotherapy. The primary endpoint was overall survival (
Jian-Ming Xu   +35 more
semanticscholar   +1 more source

Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma

open access: yesJAMA Oncology, 2022
Key Points Question Does immunotherapy confer a survival benefit for patients with advanced esophageal squamous cell carcinoma and low expression of programmed death ligand 1?
D. Yap   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy